| Similar Articles |
|---|
 |
Chemistry World
November 4, 2015
Phillip Broadwith |
Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema.   |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
March 27, 2009
Brian Orelli |
Dyax: A Cinderella Story Ends in a Fall FDA asks Dyax for more information. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
December 3, 2009
Brian Orelli |
I Love This Industry With double-digit gains, how could you not love the biotech industry? |
The Motley Fool
August 31, 2011
Brian Orelli |
Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease. |
The Motley Fool
July 16, 2008
Brian Lawler |
A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
December 27, 2010
Brian Orelli |
FDA Kicks Dust on Alimera's Fairy Tale Eight months after its IPO, Alimera gets hammered. |
The Motley Fool
July 28, 2010
Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different? |
The Motley Fool
May 26, 2009
Brian Orelli |
Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected. |
The Motley Fool
March 13, 2009
Brian Orelli |
Will These Drugs Get Past the FDA? Let's take a look at which pharma companies are hoping to score with the FDA this month. |
HHMI Bulletin
February 2011
Michele Solis |
Right Before Your Eyes Coupling protein sequence to function, thousands of variants at a time. |
The Motley Fool
February 20, 2007
Brian Lawler |
Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead. |
